Pembrolizumab, an immune checkpoint inhibitor, has been approved by the US Food and Drug Administration for the treatment of ...

A grandad with advanced lung cancer which often leaves patients dead within four months has become free of the disease after ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

A new research paper was published in Volume 16 of Oncotarget on June 10, 2025, titled "Exceptional responders to ...

Douglas Adkins, MD, discusses future directions of the KEYNOTE-689 trial of pembrolizumab in head and neck cancer following the agent's FDA approval.

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to advance at a resilient ...

Our case series adds to published data from early-phase trials supporting the promise of immunotherapy in some patients with PC."BUFFALO, NY – June ...

Atezolizumab did not confer any benefits when added to SBRT in a phase 3 trial of patients with inoperable, early-stage NSCLC.

The recent experience of Chinese biotech companies in developing their own drug candidates and inking deals with larger ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...